BioSpace News Archive

A group of researchers from UCLA have developed a spray gel that contains immune-stimulating drugs. The gel was effective about 50 percent of the time in stimulating laboratory animals’ immune systems to stop cancer from recurring and inhibiting its metastases.

KaNDy Therapeutics, a clinical-stage company developing a potential breakthrough non-hormonal treatment for multiple debilitating symptoms of the menopause, today announces initiation of the Phase 2b clinical trial evaluating NT-814 in women with troublesome symptoms of the menopause.

NOXXON Pharma N.V. announced today the details of its participation at the ESMO Immuno-Oncology Congress on December 13-16, 2018 at the Palexpo Exhibition Center, 30 Route François-Peyrot, 1218 Le Grand-Saconnex, in Geneva, Switzerland.

White Americans make up the vast majority of clinical trial participants, despite evidence that some cancers affect minority populations in greater numbers.

The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.

Flexible hours. More vacation time. Work from home. Free gym memberships. Free snacks. Company-sponsored outings. Student loan payment assistance. These are some of the perks that companies dangle in order to attract top talent to their ranks.

The new Planmeca Compact™ i5 dental unit has been built around five central themes – design, wellbeing, cleanliness, intelligence, and evolution. All of these principles are carried through in every detail of the dental unit, resulting in a perfect combination of functionality, durability, comfort, safety, and aesthetics.

COUG plans to partner with additional urology groups to provide practice management services in Ohio and strategic markets throughout the country.

BACH uplevels the in-person, at-home experience--and transforms lives and lifestyles

ChromaCode, Inc., a company redefining molecular testing through data science, today announced the commercial launch of its first-ever multiplex test using the Company’s proprietary High Definition Polymerase Chain Reaction (HDPCR™) technology.